MFN's First Audit: How 16 of 17 White House Pricing Deals Just Raised Prices Anyway.

On February 5, 2026, in the South Court Auditorium of the White House, President Trump unveiled TrumpRx.gov as “one of the most transformative healthcare initiatives of all time.”

The same week — and every week since — pharmaceutical companies that had signed Most-Favored-Nation pricing agreements with the administration were raising their list prices.

Not lowering. Raising.

By the second week of January 2026, drug companies had hiked list prices on 872 brand-name medicines, a median increase of 4% — identical to 2025. According to drug-pricing research nonprofit 46brooklyn, all 16 companies that had publicly committed to MFN deals contributed to the increases. Pfizer alone raised prices on 72 products, including a 15% increase on its COVID-19 vaccine.

When NPR pressed the White House about the January hikes, the response was simple: list prices don’t really matter.

Eight months into the largest voluntary drug-pricing initiative in U.S. history, the administration is now arguing that the prices the industry publishes — the prices used as benchmarks in every reference-pricing system from Brussels to Beijing — are irrelevant.

Market-access professionals know exactly how wrong that is.

On March 18, 2026, Reuters published a comparison no one in the White House wanted to see. The methodology was straightforward: take the 54 medicines available on TrumpRx.gov, compare each one to the publicly available NHS pharmacy reimbursement price in the United Kingdom.

The result: about one-third of the drugs on TrumpRx were cheaper in the UK than in the United States.

Pfizer’s arthritis pill Xeljanz. AstraZeneca’s diabetes drug Farxiga. GSK’s lung-disease inhalers. Each between 67% and 82% cheaper under the British system than on the “Most Favored Nation” portal designed to deliver the lowest prices anywhere in the world.

The President had claimed publicly that some TrumpRx medicines were “300% to 600%” cheaper than international peers — a figure Reuters noted is mathematically impossible. A discount cannot exceed 100%.

Aaron Kesselheim, professor of medicine at Harvard Medical School, told Reuters what every payer in Europe already understood: the deals are “voluntary with no enforcement measures and do not broadly address the policy issues that lead to high prices.”

There is a more polite way to say this. There is no more accurate way.

Buried under the TrumpRx fanfare, something genuinely consequential happened on January 1, 2026.

The first ten Medicare-negotiated drug prices took effect. These were the prices CMS negotiated under the Inflation Reduction Act — the Biden-era statute the current administration has loudly criticized and quietly continued. The discounts ranged from 38% on Imbruvica to 79% on Januvia.

Eliquis, the blood thinner, dropped 43%. Jardiance, the Type 2 diabetes therapy, dropped 44%. Both were on the first negotiation list.

CMS estimates these reductions will save Medicare roughly $6 billion annually and cut beneficiary out-of-pocket costs by $1.5 billion. On November 25, 2025, the administration confirmed negotiated prices for fifteen additional drugs taking effect January 1, 2027, with discounts ranging from 38% to 84% and estimated savings of $12 billion annually.

Antonio Ciaccia, CEO of 46brooklyn, was direct in his assessment: Medicare drug-price negotiation was “the straw that broke the camel’s back” on certain list-price reductions. The voluntary MFN deals weren’t.

The policy that worked was the statutory one. The policy that didn’t was the one with the cameras.

TrumpRx is not a pricing reform. It is a coupon directory.

The platform launched on February 6, 2026, with roughly 54 medicines from 16 manufacturers. The structure: a user prints a coupon, brings it to a pharmacy, and receives a cash-pay discount. The discount does not apply to anyone using insurance — which is approximately 85% of insured Americans, whose copays are often lower than the TrumpRx cash price anyway.

A closer look at the catalog reveals the design.

Branded products competing with cheaper generics. Pfizer’s Colestid is listed at $127.91 — “50% off.” The generic costs about $17 on Mark Cuban’s Cost Plus Drugs. Pfizer’s branded hydrocortisone Cortef is $45 on TrumpRx. The generic is a fraction of that anywhere else.

Off-patent blockbusters dressed as discounts. AbbVie’s Humira was added at $950 per dose, down from a list price of nearly $7,000. Humira lost patent protection in 2023. Two biosimilars on TrumpRx itself are listed at $207.60.

Combination therapies missing their other half. The HIV drug Viracept appears at $607.20 — useful only when combined with other antiretrovirals that aren’t on the platform.

Existing manufacturer programs rebranded. Wegovy is offered at $149/month for the 4mg dose, valid until April 15, 2026, after which it rises to $199. This is the identical price already available on Novo Nordisk’s NovoCare direct-to-consumer portal. The TrumpRx coupon does not provide a discount the manufacturer wasn’t already offering.

Wayne Winegarden of the Pacific Research Institute, a right-leaning think tank not generally inclined to criticize the administration, told Reuters that TrumpRx has only set “a rough ceiling on what Americans paying cash might spend out of pocket” — not made medicines more affordable.

Sean Tu, a patent-law expert at the University of Alabama, was sharper: by listing branded drugs against generic alternatives, “branded companies aren’t making a sacrifice by offering them at lower costs as reflected on Trump’s portal. That’s a sale they would not have made if not for TrumpRx.”

The portal isn’t lowering prices. It is creating a cash-pay segment that didn’t previously exist for branded products — at prices the manufacturer chose, defended, and locked in.

If the U.S. side of the MFN story is theater, the European side is structural.

Since President Trump signed the May 12, 2025 executive order launching the MFN initiative, drug launches in EU markets have fallen 35%. Withdrawals have risen 43%. The EFPIA W.A.I.T. Indicator — the industry’s annual measure of time from EMA approval to patient access — recorded 578 days on average for 2025, more than a month longer than 2024.

The pattern is no longer anecdotal:

• Insmed paused European and U.K. launches of Brinsupri after EMA approval in November 2025. CEO William Lewis told analysts in February 2026: “MFN has caused us to pause our launch efforts in Europe and the U.K. We will wait for clarity.” Brinsupri is still not commercially available in any European market.

• Amgen withdrew Repatha from Denmark, citing prices and a “changed environment.”

• Indivior pulled Subutex and Suboxone from Sweden and other markets.

• France’s Haute Autorité de Santé issued only 10 early-access decisions in 2025, down from 25 in 2024 — a 60% collapse.

Lionel Collet, head of HAS, was unusually direct in March 2026: “Manufacturers all talk to me about Trump, since the autumn. It’s all about the policy in the U.S. and what it means for Europe.”

Over 90% of drugs approved globally in 2025 launched in the U.S. first. Most have still not reached European patients.

The commercial logic now driving these decisions is simple, and it is impossible to refute in a board meeting:

“If MFN ties my U.S. Medicaid price to the lowest published price in a basket of developed economies that includes the EU, and the EU price is set through a national HTA process I cannot control, then every euro I concede in Berlin or Paris becomes a dollar I lose in Boston. The rational launch decision is to delay, withdraw, or skip Europe entirely until the U.S. policy stabilizes.”

This is not industry rhetoric. This is the launch sequencing being executed in real time across mid-cap and large-cap biopharma. Charles River Associates VP Matthew Majewski has confirmed publicly that the question on his team’s desks is no longer whether to launch in MFN reference markets, but how.

Stefan Oelrich, EFPIA president and senior Bayer executive, told Reuters in March 2026 that the industry is seeing “first signs of delayed introductions into Europe” as a direct consequence of MFN uncertainty.

Europe has become collateral damage in a U.S. policy that didn’t even lower U.S. prices.

There is a reason every market-access leader who modeled the MFN deals in October 2025 reached the same conclusion: the architecture is broken.

Voluntary deals without enforcement are commitments, not contracts. Unlike the IRA’s negotiated prices — which are statutory, time-bound, and binding — the MFN agreements include no enforcement mechanism, no list-price freeze, no penalty for January increases. They are press releases. The proof: 16 of 17 signatories raised list prices within twelve weeks of signing.

List prices and net prices have been separated for decades. Pfizer told NPR explicitly that while its list prices rose in January 2026, “the prices insurance companies pay them have gone down because of bigger rebates and discounts.” This is true. It is also the exact reason the MFN architecture cannot work: the published price — the only price visible to international reference systems — remains the lever pharma controls. The net price, which determines what the U.S. system actually pays, is hidden inside PBM contracts no MFN deal touches.

Cash-pay portals reach the wrong patients. Roughly 85% of insured Americans cannot use TrumpRx discounts in any economically meaningful way. The discounts are concentrated in categories — obesity, fertility, erectile dysfunction — that commercial insurance frequently excludes. This is not a policy serving the median U.S. patient. It is a discount channel for the uninsured cash-payer segment, expanded with federal branding.

There is no mechanism to raise foreign prices. The original MFN logic required other developed nations to pay more, so the U.S. could pay less while preserving global pharma revenue. No such mechanism exists. The administration cannot raise the price IQWiG accepts for a new drug in Germany. It cannot raise the NHS reimbursement in the UK. It cannot reopen French CEPS price negotiations. The lever was always missing.

What it could do — and what it has done — is make the U.S. so commercially unpredictable that European launches become rational only when MFN exposure can be contained. Which is to say: rarely.

The MFN audit is now substantively complete. The data is public, the patterns are stable, and the strategic implications are clear.

For market-access, pricing, and HEOR teams, three takeaways matter.

1. List-price discipline now has a measurable opportunity cost. Companies that maintained or raised U.S. list prices in January 2026 demonstrably suffered no consequences from the White House deals. Those that conceded — particularly through visible cash-pay discounts that international reference systems can detect — created exposure they may regret. Pricing committees that build 2027 launch waterfalls should treat the January 2026 data as the empirical baseline for what voluntary U.S. commitments actually require.

2. Europe will not protect itself in the next 18 months. The EU Pharma Package and the Critical Medicines Act, both finalized in 2026, address regulatory architecture and supply-chain resilience. Neither contains a pricing shield against U.S. reference-pricing exposure. South Korea built one in March 2026 — its dual-pricing system separating list price from confidential transaction price. Brussels has not, will not in 2026, and the political appetite to do so is not yet visible. Companies planning European launches should price as though the MFN cascade is permanent, because functionally it is.

3. The Medicare Negotiation pathway is the only pricing mechanism that has actually reduced U.S. prices. It will expand. The third negotiation cycle was announced on January 27, 2026 — 15 new drugs, including the first Medicare Part B products. By 2029, the program reaches 20 drugs annually. For products with high Medicare exposure in the seven-year lookback window, the IRA timeline is now the dominant variable in net-revenue modeling. Not MFN. Not TrumpRx. Not tariffs. The negotiation list.

When the EU Pharma Package’s final texts were published on March 6, 2026 — twenty days before South Korea passed its pricing overhaul — the comparison was uncomfortable.

Korea built a dual-pricing architecture that explicitly defends against international reference-pricing cascades. The Pharma Package did not. Korea compressed orphan reimbursement to 100 days. The Pharma Package compressed EMA assessment from 210 days to 180 — leaving national P&R untouched. Korea reformed the commercial logic. Europe reformed the regulatory paperwork.

Meanwhile, the data accumulates. The launches that aren’t happening. The withdrawals that are. The 35% decline that EFPIA documented and the European Commission’s spokesperson said in March it was “too early to draw definitive conclusions” about.

It is not too early. It is, at this point, embarrassingly late.

The MFN audit has produced a clear finding: a voluntary, list-price-blind, enforcement-free pricing reform reduced no prices in America and broke launch sequencing in Europe. The architecture failed exactly the way market-access professionals predicted it would.

The remaining question is not whether the policy worked. It didn’t.

The remaining question is whether Europe will look at Korea’s example, the EFPIA W.A.I.T. data, the 35% launch decline, and the Insmed precedent — and finally build the pricing infrastructure required to defend its own patients.

Or whether Brussels will keep doing what Brussels does: study the problem for another cycle.

Beyond Approval publishes weekly strategic intelligence on market access, HTA, pricing, and regulatory shifts that reshape how medicines reach patients.